This HTML5 document contains 52 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n19http://localhost/temp/predkladatel/
n10http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n7http://linked.opendata.cz/ontology/domain/vavai/
n15http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11130%2F14%3A10283044%21RIV15-MSM-11130___/
shttp://schema.org/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n13http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n9http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11130%2F14%3A10283044%21RIV15-MSM-11130___
rdf:type
n7:Vysledek skos:Concept
rdfs:seeAlso
http://dx.doi.org/10.1186/1471-230X-14-53
dcterms:description
Background: Patients aged 65 years and older represent the majority of patients with metastatic colorectal cancer (mCRC). However, this patient population is often underrepresented in clinical trials and probably undertreated in the clinical practice. Methods: We have analysed the outcomes of 3,187 mCRC patients treated with first-line bevacizumab based on data from the Czech national registry of mCRC patients aiming to compare the treatment efficacy and safety according to the age categories. Results: In total, 2,126 (66.7%), 932 (29.2%), and 129 (4.0%) patients were aged < 65 years, 65 to 75 years, and 75+ years, respectively. Median progression-free survival (PFS) was 11.4, 11.3, and 11.8 months for patients aged < 65 years, 65 to 75 years, and 75+ years, respectively (p = 0.94). Median overall survival (OS) was 26.9, 27.5, and 25.1 months for patients aged < 65 years, 65 to 75 years, and 75+ years, respectively (p = 0.73). Using multivariable Cox model for both PFS and OS, the patient age was not significantly associated with either PFS or OS. No increase in bevacizumab-related toxicity was observed among the elderly mCRC patients with the exception of hypertension, which was observed in 71 (3.3%), 34 (3.6%), and 10 (7.8%) patients aged < 65 years, 65 to 75 years, and 75+ years, respectively. Conclusions: The results of the present study suggest similar outcome in terms of OS and PFS with bevacizumab-containing therapy in elderly mCRC patients fit for chemotherapy combined with targeted therapy compared to younger patients. Thus, chronological age should not be considered to represent a limitation in prescribing bevacizumab-containing therapy in mCRC patients. Background: Patients aged 65 years and older represent the majority of patients with metastatic colorectal cancer (mCRC). However, this patient population is often underrepresented in clinical trials and probably undertreated in the clinical practice. Methods: We have analysed the outcomes of 3,187 mCRC patients treated with first-line bevacizumab based on data from the Czech national registry of mCRC patients aiming to compare the treatment efficacy and safety according to the age categories. Results: In total, 2,126 (66.7%), 932 (29.2%), and 129 (4.0%) patients were aged < 65 years, 65 to 75 years, and 75+ years, respectively. Median progression-free survival (PFS) was 11.4, 11.3, and 11.8 months for patients aged < 65 years, 65 to 75 years, and 75+ years, respectively (p = 0.94). Median overall survival (OS) was 26.9, 27.5, and 25.1 months for patients aged < 65 years, 65 to 75 years, and 75+ years, respectively (p = 0.73). Using multivariable Cox model for both PFS and OS, the patient age was not significantly associated with either PFS or OS. No increase in bevacizumab-related toxicity was observed among the elderly mCRC patients with the exception of hypertension, which was observed in 71 (3.3%), 34 (3.6%), and 10 (7.8%) patients aged < 65 years, 65 to 75 years, and 75+ years, respectively. Conclusions: The results of the present study suggest similar outcome in terms of OS and PFS with bevacizumab-containing therapy in elderly mCRC patients fit for chemotherapy combined with targeted therapy compared to younger patients. Thus, chronological age should not be considered to represent a limitation in prescribing bevacizumab-containing therapy in mCRC patients.
dcterms:title
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
skos:prefLabel
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
skos:notation
RIV/00216208:11130/14:10283044!RIV15-MSM-11130___
n5:aktivita
n12:I n12:N
n5:aktivity
I, N
n5:cisloPeriodika
March
n5:dodaniDat
n9:2015
n5:domaciTvurceVysledku
n10:5239249
n5:druhVysledku
n14:J
n5:duvernostUdaju
n17:S
n5:entitaPredkladatele
n15:predkladatel
n5:idSjednocenehoVysledku
13809
n5:idVysledku
RIV/00216208:11130/14:10283044
n5:jazykVysledku
n8:eng
n5:klicovaSlova
Progression-free survival; Overall survival; Elderly patients; Chemotherapy; Anti-angiogenic therapy
n5:klicoveSlovo
n6:Chemotherapy n6:Overall%20survival n6:Progression-free%20survival n6:Anti-angiogenic%20therapy n6:Elderly%20patients
n5:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n5:kontrolniKodProRIV
[F5DB01D912DF]
n5:nazevZdroje
BMC Gastroenterology
n5:obor
n16:FD
n5:pocetDomacichTvurcuVysledku
1
n5:pocetTvurcuVysledku
11
n5:rokUplatneniVysledku
n9:2014
n5:svazekPeriodika
14
n5:tvurceVysledku
Melichar, Bohuslav Tomasek, Jiří Majek, Ondrej Slavicek, Lubomir Finek, Jindřich Prausová, Jana Dušek, Ladislav Büchler, Tomáš Pavlik, Tomas Vyzula, Rostislav Bortlicek, Zbynek
n5:wos
000334417600002
s:issn
1471-230X
s:numberOfPages
8
n13:doi
10.1186/1471-230X-14-53
n19:organizacniJednotka
11130